FDA Centralizes Internal Procedure For SEC Communications
This article was originally published in The Gray Sheet
Executive Summary
FDA's new process for referring information to the Securities & Exchange Commission could result in heightened CDRH attention to potentially false or misleading statements by device firms
You may also be interested in...
SEC Suspends BioCurex Trading, Questions Firm’s Regulatory Claims
Press releases claiming "FDA-approved" status for BioCurex' Class I Histo-RECAF alpha-fetoprotein (AFP) tissue staining test played a role in SEC's decision to halt trading of the company's stock April 8
FDA/SEC Communication Enhancement Effort Gauged At FDLI
Device manufacturers should take extra care to present a uniform message to FDA and CMS concerning new devices to avoid running afoul of the Securities & Exchange Commission, Latham & Watkins Partner John Manthei advised April 15
SEC Suspends BioCurex Trading, Questions Firm’s Regulatory Claims
Press releases claiming "FDA-approved" status for BioCurex' Class I Histo-RECAF alpha-fetoprotein (AFP) tissue staining test played a role in SEC's decision to halt trading of the company's stock April 8